234 related articles for article (PubMed ID: 25302557)
1. Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease.
Kortüm KM; Langer C; Monge J; Bruins L; Egan JB; Zhu YX; Shi CX; Jedlowski P; Schmidt J; Ojha J; Bullinger L; Liebisch P; Kull M; Champion MD; Van Wier S; Ahmann G; Rasche L; Knop S; Fonseca R; Einsele H; Stewart AK; Braggio E
Br J Haematol; 2015 Feb; 168(4):507-10. PubMed ID: 25302557
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P).
Kortüm KM; Langer C; Monge J; Bruins L; Zhu YX; Shi CX; Jedlowski P; Egan JB; Ojha J; Bullinger L; Kull M; Ahmann G; Rasche L; Knop S; Fonseca R; Einsele H; Stewart AK; Braggio E
Ann Hematol; 2015 Jul; 94(7):1205-11. PubMed ID: 25743686
[TBL] [Abstract][Full Text] [Related]
3. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy.
Boyd KD; Ross FM; Tapper WJ; Chiecchio L; Dagrada G; Konn ZJ; Gonzalez D; Walker BA; Hockley SL; Wardell CP; Gregory WM; Child JA; Jackson GH; Davies FE; Morgan GJ;
Genes Chromosomes Cancer; 2011 Oct; 50(10):765-74. PubMed ID: 21961181
[TBL] [Abstract][Full Text] [Related]
4. The spectrum of TP53 mutations in bladder carcinoma.
Williamson MP; Elder PA; Knowles MA
Genes Chromosomes Cancer; 1994 Feb; 9(2):108-18. PubMed ID: 7513540
[TBL] [Abstract][Full Text] [Related]
5. A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma.
Jiménez C; Jara-Acevedo M; Corchete LA; Castillo D; Ordóñez GR; Sarasquete ME; Puig N; Martínez-López J; Prieto-Conde MI; García-Álvarez M; Chillón MC; Balanzategui A; Alcoceba M; Oriol A; Rosiñol L; Palomera L; Teruel AI; Lahuerta JJ; Bladé J; Mateos MV; Orfão A; San Miguel JF; González M; Gutiérrez NC; García-Sanz R
J Mol Diagn; 2017 Jan; 19(1):99-106. PubMed ID: 27863261
[TBL] [Abstract][Full Text] [Related]
6. High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma.
Thakurta A; Ortiz M; Blecua P; Towfic F; Corre J; Serbina NV; Flynt E; Yu Z; Yang Z; Palumbo A; Dimopoulos MA; Gutierrez NC; Goldschmidt H; Sonneveld P; Avet-Loiseau H
Blood; 2019 Mar; 133(11):1217-1221. PubMed ID: 30692124
[TBL] [Abstract][Full Text] [Related]
7. Novel genomic findings in multiple myeloma identified through routine diagnostic sequencing.
Ryland GL; Jones K; Chin M; Markham J; Aydogan E; Kankanige Y; Caruso M; Guinto J; Dickinson M; Prince HM; Yong K; Blombery P
J Clin Pathol; 2018 Oct; 71(10):895-899. PubMed ID: 29760015
[TBL] [Abstract][Full Text] [Related]
8. N-ras and p53 gene mutations are very rare events in multiple myeloma.
Yasuga Y; Hirosawa S; Yamamoto K; Tomiyama J; Nagata K; Aokia N
Int J Hematol; 1995 Aug; 62(2):91-7. PubMed ID: 8590778
[TBL] [Abstract][Full Text] [Related]
9. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma.
Lodé L; Eveillard M; Trichet V; Soussi T; Wuillème S; Richebourg S; Magrangeas F; Ifrah N; Campion L; Traullé C; Guilhot F; Caillot D; Marit G; Mathiot C; Facon T; Attal M; Harousseau JL; Moreau P; Minvielle S; Avet-Loiseau H
Haematologica; 2010 Nov; 95(11):1973-6. PubMed ID: 20634494
[TBL] [Abstract][Full Text] [Related]
10. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
[TBL] [Abstract][Full Text] [Related]
11. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.
Drach J; Ackermann J; Fritz E; Krömer E; Schuster R; Gisslinger H; DeSantis M; Zojer N; Fiegl M; Roka S; Schuster J; Heinz R; Ludwig H; Huber H
Blood; 1998 Aug; 92(3):802-9. PubMed ID: 9680348
[TBL] [Abstract][Full Text] [Related]
12. Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines.
Concin N; Zeillinger C; Tong D; Stimpfl M; König M; Printz D; Stonek F; Schneeberger C; Hefler L; Kainz C; Leodolter S; Haas OA; Zeillinger R
Breast Cancer Res Treat; 2003 May; 79(1):37-46. PubMed ID: 12779080
[TBL] [Abstract][Full Text] [Related]
13. Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis.
Greipp PT; Smoley SA; Viswanatha DS; Frederick LS; Rabe KG; Sharma RG; Slager SL; Van Dyke DL; Shanafelt TD; Tschumper RC; Zent CS
Br J Haematol; 2013 Nov; 163(3):326-33. PubMed ID: 24032430
[TBL] [Abstract][Full Text] [Related]
14. Incidence of chromosome numerical changes in multiple myeloma: fluorescence in situ hybridization analysis using 15 chromosome-specific probes.
Tabernero D; San Miguel JF; Garcia-Sanz M; Nájera L; García-Isidoro M; Peréz-Simon JA; Gonzalez M; Wiegant J; Raap AK; Orfão A
Am J Pathol; 1996 Jul; 149(1):153-61. PubMed ID: 8686739
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance.
Vikova V; Jourdan M; Robert N; Requirand G; Boireau S; Bruyer A; Vincent L; Cartron G; Klein B; Elemento O; Kassambara A; Moreaux J
Theranostics; 2019; 9(2):540-553. PubMed ID: 30809292
[TBL] [Abstract][Full Text] [Related]
16. Myelodysplasia during the course of myeloma. Restriction of 17p deletion and p53 overexpression to myeloid cells.
Soenen V; Preudhomme C; Roumier C; Laï JL; Lepelley P; Facon T; Pagniez D; Fenaux P
Leukemia; 1998 Feb; 12(2):238-41. PubMed ID: 9519788
[TBL] [Abstract][Full Text] [Related]
17. [Gene Mutation and Overexpression of Newly Diagnosed Multiple Myeloma Patients].
Fan Y; Wang SJ; Liu YF; Wang C; Li YF; Wang WQ; Hao QQ; Zhang DF; Li YM; Sun H; Guo R; Chen SQ; Xie XS; Li T; Wan DM; Jiang ZX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):166-169. PubMed ID: 35123621
[TBL] [Abstract][Full Text] [Related]
18. Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis.
Kim SJ; Shin HT; Lee HO; Kim NK; Yun JW; Hwang JH; Kim K; Park WY
Oncotarget; 2016 Oct; 7(42):68350-68359. PubMed ID: 27634910
[TBL] [Abstract][Full Text] [Related]
19. [The bewildering complexity of cancer].
Jordan B
Med Sci (Paris); 2011; 27(8-9):781-6. PubMed ID: 21880268
[No Abstract] [Full Text] [Related]
20. Molecular genetic studies of tumor suppressor gene regions on chromosomes 13 and 17 in colorectal tumors.
Lothe RA; Fossli T; Danielsen HE; Stenwig AE; Nesland JM; Gallie B; Børresen AL
J Natl Cancer Inst; 1992 Jul; 84(14):1100-8. PubMed ID: 1619684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
